Business Wire

Nearly 50% of Pandemic Costs Will Fall on Advanced Economies, World Government Summit Report Finds

5.5.2021 14:45:00 EEST | Business Wire | Press release

Share

A seminal report launched by the World Government Summit Organization (WGS) which highlights 21 critical priorities within five focus areas offers a source of direction for governments as they tackle post-COVID-19 recovery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005573/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The new WGS report ‘21 Priorities for Governments in 2021’ identifies five critical priorities in post-pandemic recovery (Photo: AETOSWire)

Wealthier economies will shoulder almost half the cost of the COVID-19 crisis, which could reach up to US$3.8 trillion in 2021, the report finds. That, even if developed economies can vaccinate their entire populace and developing economies can reach a 50 percent vaccination rate.

The report says mental health wellness, climate change and women’s empowerment are central concerns that will exacerbate if governments do not rebuild in a holistic, proactive manner.

His Excellency Mohammad Abdullah Al Gergawi, UAE Minister of Cabinet Affairs and Chairman of the World Government Summit Organization, said: “2020 will be remembered by history as the year of great disruption. While the world was woefully unprepared for the voracity of the virus, 2021 needs to be the year that defines humanity’s future and reshape societies to become stronger and more resilient.”

He added: “With great change comes great opportunity. Valuable lessons emerged over the past year, which we must heed as we recover. Our individual and collective actions as nations have important consequences not only for us, but for our children and the many generations to come after them: we must all be accountable to ourselves and each other.”

With governments’ focus trained on the pandemic over the last 18 months, underlying societal issues such as the mental health and climate crises have exacerbated, and could become as problematic as the public health emergency if leaders do not adapt their thinking, the report suggests.

The 21 priorities outlined by the report are broken down into five sections:

These five focus areas are:

  1. Reimagining and Reinforcing Key Public Institutions
  2. Competing in a Transformed Economy
  3. Navigating a Transformed Geo-Technical Order
  4. Repairing the Social Fabric
  5. Securing the Future

Please download the full report here:

About WGS:

The World Government Summit Organization is a global, neutral, non-profit organization dedicated to shaping the future of governments. The Summit, in its various activities, explores the agenda of the next generation of governments, focusing on harnessing innovation and technology to solve universal challenges facing humanity.

The World Government Summit Organization operates at the intersection of government and innovation. It functions as a knowledge exchange platform that convenes leaders in the public and private sectors to collaborate with world-renowned experts in creating positive impact for citizens around the world. Including initiatives and events held throughout the year, the World Government Summit holds a flagship annual gathering in Dubai.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mahmoud Kandil, +97155126 6801
mkandil@apcoworldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye